Table 1.
Characteristics of the studies presenting results of avelumb and pembrolizumab for GTN treatment included in this systematic review.
| Immunotherapy | Authors | Year | Type | Journal | Country | Number of case(s) |
|---|---|---|---|---|---|---|
| Avelumab | You et al. | 2020 | Clinical trial | Journal of Clinical Oncology | France | 15 |
| Pembrolizumab | Ghorani et al. | 2017 | Case series / Correspondence | Lancet | UK | 4 |
| Huang et al. | 2017 | Case report / Correspondence | Journal of Clinical Oncology | US | 1 | |
| Choi et al. | 2019 | Case report | European Journal of Cancer | South Korea | 2 | |
| Clair et al. | 2020 | Case report | Gynecologic Oncology Reports | US | 1 | |
| Goldfarb et al. | 2020 | Case report / Correspondence | Gynecologic Oncology Reports | US | 1 | |
| Pisani et al. | 2021 | Case report | Current Oncology | Malta | 1 | |
| Bell et al. | 2021 | Case report | Gynecologic Oncology Reports | US | 1 | |
| Porter et al. | 2021 | Case report | Gynecologic Oncology Reports | US/UK | 1 | |
| Polnaszek et al. | 2021 | Case report | Obstetrics & Gynecology | US | 1 | |
| Paspalj et al. | 2022 | Case report | Gynecologic Oncology Reports | Austria | 1 | |
| Wong et al. | 2022 | Case report | Gynecologic Oncology Reports | US | 1 |